N.J. U.S. Attorney: Drug Manufacturer to Pay $2.25 Million to Settle Controlled Substances Act Allegations
April 11, 2024
April 11, 2024
NEWARK, New Jersey, April 11 -- The office of the U.S. Attorney for the District of New Jersey issued the following news release on April 10, 2024:
A pharmaceutical manufacturer agreed to pay $2.25 million to resolve allegations that it violated the Controlled Substances Act (CSA), U.S. Attorney Philip Sellinger announced today.
The manufacturer, Novel Laboratories Inc. (Novel), a subsidiary of Lupin Inc., also reached an administrative resolution with the Drug Enforcem . . .
A pharmaceutical manufacturer agreed to pay $2.25 million to resolve allegations that it violated the Controlled Substances Act (CSA), U.S. Attorney Philip Sellinger announced today.
The manufacturer, Novel Laboratories Inc. (Novel), a subsidiary of Lupin Inc., also reached an administrative resolution with the Drug Enforcem . . .